EVOFEM BIOSCIENC(EVFM) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 — Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO, CA, November 14, 2024 — Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter an ...